Inventiva S.A. IVA
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Inventiva S.A. (IVA) is a healthcare company listed in the US with a market value of about $870M. In fiscal year 2025 it had revenue of $5M and net income of -$390M, a net margin of -7899.6%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 4% a year, a 5-year average ROIC of -120%.
About Inventiva
Inventiva is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $8M in 2018 to $5M in 2025, a decline of about 7.4% a year. It was profitable in 0 of the last 8 years in our data. Its share count fell by 21% over three years (buybacks).
Score: 0.6 / 5
Checks passed
- 3-year revenue growth above 10% a year
- More cash than debt, or low debt to equity
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $15M | $26M | $20M | $10M | $6M | $13M | $8M |
| Net income | -$390M | -$191M | -$122M | -$58M | -$56M | -$41M | -$34M | -$38M |
| Free cash flow | -$116M | -$89M | — | — | -$54M | -$38M | — | — |
| EPS (diluted) | $-2.09 | $-0.81 | $-0.52 | $-0.24 | $-0.24 | $-0.17 | $-0.14 | $-0.16 |
| Net margin | -7899.6% | -1251.0% | -476.7% | -288.5% | -583.9% | -638.8% | -267.6% | -447.4% |
| ROIC | — | — | -368.0% | -50.2% | -41.6% | -19.4% | -57.7% | -42.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Inventiva pay a dividend?
Not currently.
Is Inventiva a good stock to buy?
We do not give buy or sell advice. Inventiva scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.